Clinical Trials Browser

Myelodysplastic Syndromes × Emapalumab × 90 days × Clear all

NCT06996119 2026-05-11

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute